Survival and Quality-of-life Outcomes in Early-Stage NSCLC Patients: a Literature Review of Real-World Evidence

References

• American Cancer Society . Key Statistics for Lung Cancer (2022). www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html
   Google Scholar
• Sung H , Ferlay J , Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Duma N , Santana-Davila R , Molina JR . Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94(8), 1623–1640 (2019).
   PubMed Web of Science ®Google Scholar
• World Health Organization . International Agency for Research on Cancer Globocan Europe Fact Sheet 2020 (2020). https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf
   Google Scholar
• American Society of Clinical Oncology . Lung cancer – non-small cell: introduction (2021). www.cancer.net/cancer-types/lung-cancer-non-small-cell/introduction
   Google Scholar
• Soerjomataram I , Lortet-Tieulent J , Parkin DM et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380(9856), 1840–1850 (2012).
   PubMed Web of Science ®Google Scholar
• Goldstraw P , Chansky K , Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for Revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 11(1), 39–51 (2016).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute . Recurrent cancer: when cancer comes back (2020). www.cancer.gov/types/recurrent-cancer#:~:text=Regional%20recurrence%20means%20that%20the,called%20metastasis%20or%20metastatic%20cancer
   Google Scholar
• National Comprehensive Cancer Network . Lung cancer – early and locally advanced: non-small-cell lung cancer (2019). www.nccn.org/patients/guidelines/content/PDF/lung-early-stage-patient.pdf
   Google Scholar
• American Lung Association . State of Lung Cancer 2020 Report (2020). www.lung.org/getmedia/381ca407-a4e9-4069-b24b-195811f29a00/solc-2020-report-final.pdf
   Google Scholar
• Postmus PE , Kerr KM , Oudkerk M et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(Suppl. 4), iv1–iv21 (2017).
   PubMedGoogle Scholar
• Maniwa T , Takahashi S , Isaka M , Endo M , Ohde Y . Outcomes of initial surgery in patients with clinical N2 non-small cell lung cancer who met 4 specific criteria. Surg. Today 46(6), 699–704 (2016).
   PubMed Web of Science ®Google Scholar
• Endo C , Sakurada A , Notsuda H et al. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann. Thorac. Surg. 93(4), 1061–1068 (2012).
   PubMed Web of Science ®Google Scholar
• Janjigian YY , Park BJ , Zakowski MF et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol. 6(3), 569–575 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JS , Lee KH , Cho EK et al. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer. 122, 234–242 (2018).
   PubMed Web of Science ®Google Scholar
• Tsutani Y , Miyata Y , Kushitani K , Takeshima Y , Yoshimura M , Okada M . Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 148(4), 1179–1185 (2014).
   PubMed Web of Science ®Google Scholar
• Brandt WS , Yan W , Zhou J et al. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2–4N0–1 non-small cell lung cancer: a propensity-matched analysis. J. Thorac. Cardiovasc. Surg. 157(2), 743–753; e743 (2019).
   PubMed Web of Science ®Google Scholar
• Kneuertz PJ , D’Souza DM , Richardson M , Abdel-Rasoul M , Moffatt-Bruce SD , Merritt RE . Long-term oncologic outcomes after robotic lobectomy for early-stage non-small-cell lung cancer versus video-assisted thoracoscopic and open thoracotomy approach. Clin Lung Cancer. 21(3), 214–224; e212 (2020).
   PubMed Web of Science ®Google Scholar
• Shin DW , Cho JH , Yoo JE et al. Conditional survival of surgically treated patients with lung cancer: a comprehensive analyses of overall, recurrence-free, and relative survival. Cancer Res Treat. 53(4), 1057–1071 (2021).
   PubMed Web of Science ®Google Scholar
• Yun JK , Park I , Kim HR et al. Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: a propensity score-weighted comparison with open thoracotomy. Lung Cancer. 150, 201–208 (2020).
   PubMed Web of Science ®Google Scholar
• Landreneau RJ , Normolle DP , Christie NA et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. J. Clin. Oncol. 32(23), 2449–2455 (2014).
   PubMed Web of Science ®Google Scholar
• Schuchert MJ , Awais O , Abbas G et al. Influence of age and IB status after resection of node-negative non-small cell lung cancer. Ann. Thorac. Surg. 93(3), 929–935; discussion 935–926 (2012).
   PubMed Web of Science ®Google Scholar
• Marushima H , Kimura H , Miyazawa T et al. Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab. Anticancer Drugs 31(2), 177–182 (2020).
   PubMed Web of Science ®Google Scholar
• Park B , Lee G , Kim HK et al. A retrospective comparative analysis of elderly and younger patients undergoing pulmonary resection for stage I non-small cell lung cancer. World J Surg Oncol. 14(1), 13 (2016).
   PubMedGoogle Scholar
• Park SY , Lee JG , Kim J et al. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer. J Cardiothorac Surg. 8, 151 (2013).
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen ML , van Steenbergen LN , Steyerberg E , Visser O , De Ruysscher DK , Groen HJ . Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands. J Thorac Oncol. 7(3), 496–502 (2012).
   PubMed Web of Science ®Google Scholar
• Wang SJ , Fuller CD , Thomas CR Jr . Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol. 2(3), 180–190 (2007).
   PubMed Web of Science ®Google Scholar
• Lionikaite V , Curry A , Brown A . POSC300 validation of artificial intelligence for performing systematic literature review searching for clinical efficacy and safety data. Value in Health. 25(1), S207 (2022).
   Web of Science ®Google Scholar
• Michelson M , Dogra R , Goldberg N . Artificial intelligence derived literature searches can provide more relevant data, more quickly than traditional reference databases: a case study. Curr. Med. Res. Opin. 37, 7 (2021).
   Web of Science ®Google Scholar
• Bryant AS , Cerfolio RJ , Minnich DJ . Survival and quality of life at least 1 year after pneumonectomy. J. Thorac. Cardiovasc. Surg. 144(5), 1139–1143 (2012).
   PubMed Web of Science ®Google Scholar
• Hattori A , Matsunaga T , Takamochi K , Oh S , Suzuki K . Locoregional recurrence after segmentectomy for clinical-T1aN0M0 radiologically solid non-small-cell lung carcinoma. Eur. J. Cardiothorac. Surg. 51(3), 518–525 (2017).
   PubMed Web of Science ®Google Scholar
• Koike T , Koike T , Yoshiya K , Tsuchida M , Toyabe S . Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 146(2), 372–378 (2013).
   PubMed Web of Science ®Google Scholar
• Ostroff JS , Krebs P , Coups EJ et al. Health-related quality of life among early-stage, non-small cell, lung cancer survivors. Lung Cancer. 71(1), 103–108 (2011).
   PubMed Web of Science ®Google Scholar
• Sarna L , Cooley ME , Brown JK et al. Women with lung cancer: quality of life after thoracotomy: a 6-month prospective study. Cancer Nurs. 33(2), 85–92 (2010).
   PubMed Web of Science ®Google Scholar
• Nomori H , Mori T , Shiraishi A et al. Long-term prognosis after segmentectomy for cT1 N0 M0 non-small cell lung cancer. Ann. Thorac. Surg. 107(5), 1500–1506 (2019).
   PubMed Web of Science ®Google Scholar
• Maeda R , Yoshida J , Hishida T et al. Late recurrence of non-small cell lung cancer more than 5 years after complete resection: incidence and clinical implications in patient follow-up. Chest 138(1), 145–150 (2010).
   PubMed Web of Science ®Google Scholar
• Maeda R , Yoshida J , Ishii G et al. Long-term outcome and late recurrence in patients with completely resected stage IA non-small cell lung cancer. J. Thorac. Oncol. 5(8), 1246–1250 (2010).
   PubMed Web of Science ®Google Scholar
• Verstegen NE , Lagerwaard FJ , Hashemi SM , Dahele M , Slotman BJ , Senan S . Patterns of disease recurrence after SABR for early stage non-small-cell lung cancer: optimizing follow-up schedules for salvage therapy. J Thorac Oncol. 10(8), 1195–1200 (2015).
   PubMed Web of Science ®Google Scholar
• Butts E , Gococo-Benore D , Pai T et al. P08.05 Risk factors associated with recurrence following curative therapy for stage I NSCLC. J. Thorac. Oncol. 16(3), S283 (2021).
   Web of Science ®Google Scholar
• Kelsey CR , Marks LB , Hollis D et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 115(22), 5218–5227 (2009).
   PubMed Web of Science ®Google Scholar
• Lee BE , Port JL , Stiles BM et al. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann. Thorac. Surg. 88(4), 1100–1105 (2009).
   PubMed Web of Science ®Google Scholar
• Wada H , Toyoda T , Kaiho T et al. P2.16-44 Long-term outcome of pulmonary segmentectomy for c-IA non-small cell lung cancer. J. Thorac. Oncol. 13(10), S848–S849 (2018).
   Google Scholar
• Senthi S , Lagerwaard FJ , Haasbeek CJ , Slotman BJ , Senan S . Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 13(8), 802–809 (2012).
   PubMed Web of Science ®Google Scholar
• Andreano A , Peake MD , Janes SM et al. The care and outcomes of older persons with lung cancer in England and the United States, 2008–2012. J Thorac Oncol. 13(7), 904–914 (2018).
   PubMed Web of Science ®Google Scholar
• Driessen EJ , Aarts MJ , Bootsma GP , van Loon JG , Janssen-Heijnen ML . Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990–2014): disparities between younger and older patients. Lung Cancer. 108, 198–204 (2017).
   PubMed Web of Science ®Google Scholar
• Hechtner M , Eichler M , Wehler B et al. Quality of life in NSCLC survivors - a multicenter cross-sectional study. J Thorac Oncol. 14(3), 420–435 (2019).
   PubMed Web of Science ®Google Scholar
• Grutters JP , Joore MA , Wiegman EM et al. Health-related quality of life in patients surviving non-small cell lung cancer. Thorax 65(10), 903–907 (2010).
   PubMed Web of Science ®Google Scholar
• Pennell NA , Neal JW , Chaft JE et al. SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J. Clin. Oncol. 37(2), 97–104 (2019).
   PubMed Web of Science ®Google Scholar
• Winton T , Livingston R , Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589–2597 (2005).
   PubMed Web of Science ®Google Scholar
• Zhong WZ , Wang Q , Mao WM et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 19(1), 139–148 (2018).
   PubMed Web of Science ®Google Scholar
• Pignon J-P , Tribodet H , Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552–3559 (2008).
   PubMed Web of Science ®Google Scholar
• Lee J , Kim HK , Park BJ et al. Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. Lung Cancer. 115, 89–96 (2018).
   PubMed Web of Science ®Google Scholar
• American Cancer Society . Cancer treatment & survivorship facts & figures 2019–2021 (2019). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf
   Google Scholar
• Merrill RM , Hunter BD . Conditional survival among cancer patients in the United States. Oncologist. 15(8), 873–882 (2010).
   PubMed Web of Science ®Google Scholar
• Department of Health (Quality Health) United Kingdom . Quality of life of cancer survivors in England: report on a pilot survey using patient reported outcome measures (PROMS). Health, Do (2012). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/267042/9284-TSO-2900701-PROMS-1.pdf
   Google Scholar
• Coebergh JW , Janssen-Heijnen ML , Post PN , Razenberg PP . Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J. Clin. Epidemiol. 52(12), 1131–1136 (1999).
   PubMed Web of Science ®Google Scholar
• Sugimura H , Yang P . Long-term survivorship in lung cancer: a review. Chest 129(4), 1088–1097 (2006).
   PubMed Web of Science ®Google Scholar